Form 4: SpringWorks Therapeutics CFO Disposes of All Equity Holdings Following Merger with Merck KGaA Subsidiary

SpringWorks Therapeutics, Inc.'s Chief Financial Officer, Francis I. Perier Jr., has reported the disposition of all his beneficial ownership in the company's securities, including common stock, restricted stock units, performance share units, and stock options, as a direct result of the company's merger with EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany.

Summary

• SpringWorks Therapeutics, Inc. (SWTX) completed its merger with EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany, effective July 1, 2025.
• As a result of the merger, each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash per share.
• Francis I. Perier Jr., the Chief Financial Officer, disposed of 60,889 shares of common stock, which included 32,559 shares underlying restricted stock units (RSUs).
• All outstanding restricted stock units (RSUs) and performance share units (PSUs) were cancelled and converted into cash-based awards, with the value determined by the $47.00 merger consideration.
• Outstanding vested stock options were cancelled and converted into cash, calculated as the product of the number of shares and the excess of the $47.00 merger consideration over the option's exercise price.
• Outstanding unvested stock options were cancelled and converted into cash-based awards, with the value calculated similarly to vested options, generally retaining original vesting terms.
• A special vesting acceleration applies to both Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards, where 50% of each then-unvested tranche will vest on the nine-month anniversary of the merger's closing date, subject to continued employment.
• Any stock options with an exercise price greater than $47.00 were cancelled for no consideration.
• Following these transactions, Francis I. Perier Jr. holds 0 shares of common stock and 0 derivative securities in SpringWorks Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The sentiment is positive as the merger has successfully closed, providing a clear cash exit for shareholders and converting employee equity into valuable cash or cash-based awards, with provisions for continued employment and vesting.

Positives

• Shareholders received a cash consideration of $47.00 per share, providing a clear exit value.
• Equity awards (RSUs, PSUs, and stock options) held by employees like the CFO were converted into cash or cash-based awards, ensuring value realization for their holdings.
• The conversion of unvested equity awards into cash-based awards with a partial vesting acceleration (50% on the nine-month anniversary) provides an incentive for continued employment with the acquiring entity.

Negatives

• SpringWorks Therapeutics, Inc. ceased to be an independent publicly traded company, becoming a wholly owned subsidiary of Merck KGaA.
• Stock options with an exercise price above the $47.00 merger consideration were cancelled for no value, resulting in a loss for holders of those specific options.

Future Outlook

SpringWorks Therapeutics, Inc. is now a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany. Its future operations and strategic direction will be integrated within Merck KGaA's broader corporate strategy and financial reporting.

Industry Context

This transaction represents a significant consolidation event in the biotechnology and pharmaceutical sector, where larger pharmaceutical companies often acquire smaller, innovative biotech firms to expand their pipelines and market reach. Such mergers are common strategies for growth and intellectual property acquisition in the industry.

Comparison to Industry Standards

• The treatment of equity awards (RSUs, PSUs, and stock options) in this merger, involving conversion to cash or cash-based awards with continued vesting, aligns with common industry practices for M&A transactions, particularly in the biotech and pharma sectors.
• The provision for accelerated vesting of a portion of unvested awards (50% on the nine-month anniversary) is a typical mechanism used to incentivize key personnel, such as the CFO, to remain with the acquiring entity post-merger, ensuring continuity and knowledge transfer.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $47.00 cash per share, realizing their investment.
• Employees (including CFO): Equity awards converted to cash or cash-based awards, with incentives for continued employment under the new ownership.
• Customers/Suppliers: No direct impact indicated by this filing, but operations will now be under Merck KGaA's umbrella.
• Creditors: No specific impact mentioned, but the company's financial backing is now that of Merck KGaA.

Next Steps

• Continued employment of Francis I. Perier Jr. with the surviving entity, SpringWorks Therapeutics, Inc., now a subsidiary of Merck KGaA.
• Vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards according to their original vesting schedules, with a 50% acceleration on the nine-month anniversary of the merger closing date, subject to continued employment.

Key Dates

Keywords

Merger, Acquisition, SEC Form 4, Insider Transaction, Beneficial Ownership, SpringWorks Therapeutics, SWTX, Merck KGaA, Chief Financial Officer, Equity Compensation, Stock Options, Restricted Stock Units, Performance Share Units, Cash Consideration